LCL 161

Drug Profile

LCL 161

Alternative Names: LCL-161; NVP-LCL161; Second Mitochondria-derived Activator of Caspases (SMAC) mimetic - Novartis Oncology; SMAC mimetic LCL161

Latest Information Update: 23 Sep 2016

Price : $50

At a glance

  • Originator Novartis
  • Developer Mayo Clinic; National Cancer Institute (USA); Novartis Oncology; SCRI Development Innovations; US Oncology Research
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Multiple myeloma; Myelofibrosis
  • Phase I/II Ovarian cancer; Small cell lung cancer
  • Phase I Pancreatic cancer; Solid tumours

Most Recent Events

  • 31 Aug 2016 Novartis Pharmaceuticals plans a phase Ib trial for Colorectal cancer, Non-small cell lung cancer and Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in USA, Germany, Netherlands, Spain, United Kingdom, South Korea and Taiwan (IV) (NCT02890069)
  • 16 Apr 2016 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 107th Annual Meeting of the American Association for Cancer Research
  • 18 Feb 2016 Phase-I/II clinical trials in Ovarian cancer (Combination therapy) in USA (PO) (NCT02649673)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top